Background: B-type natriuretic peptide (BNP) and its N-terminal portion (NT-pro-BNP) are used for the assessment of cardiac dysfunction in patients with heart failure. However, it remains controversial whether or not this option is still valid in critically ill patients because of a possible interaction between the systemic inflammatory response and the natriuretic peptide levels. The aim of this study was to assess the relationship between natriuretic peptic levels, laboratory parameters of systemic inflammation, and pulmonary artery occlusion pressure (PAOP) in critically patients.

Methods: Twelve haemodyamic unstable patients, all monitored with a pulmonary artery catheter, were included in this study. Subgroups were compared using measurement values on ICU admission. Within patient associations between different variables were evaluated by a repeated measurement ancova.

Results: Acute heart failure and septic shock were diagnosed in 6 patients each. Despite significant differences in cardiac index and troponin T plasma level, BNP and NT-pro-BNP levels did not differ significantly between the two groups. Within patient, changes in BNP and NT-pro-BNP levels correlated significantly (p<0.01) with those in C-reactive protein values and those in leukocyte counts, but did not follow changes in PAOP.

Conclusion: Our results add further evidence to the hypothesis that there is an interaction between the systemic inflammatory response and the natriuretic peptides. Thus, BNP and NT-pro-BNP levels should only be used cautiously as surrogates of cardiac filling and function in haemodynamic unstable critically ill patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2007.03.108DOI Listing

Publication Analysis

Top Keywords

natriuretic peptide
12
critically ill
8
ill patients
8
b-type natriuretic
8
peptide bnp
8
bnp n-terminal
8
heart failure
8
pulmonary artery
8
bnp nt-pro-bnp
8
nt-pro-bnp levels
8

Similar Publications

Arthropod-borne viral diseases are acute febrile illnesses, sometimes with chronic effects, that can be debilitating and even fatal worldwide, affecting particularly vulnerable populations. Indigenous communities face not only the burden of these acute febrile illnesses, but also the cardiovascular complications that are worsened by urbanization. A cross-sectional study was conducted in an Indigenous population in the Northeast Region of Brazil to explore the association between arboviral infections (dengue, chikungunya, and Zika) and cardiac biomarkers, including cardiotrophin 1, growth differentiation factor 15, lactate dehydrogenase B, fatty-acid-binding protein 3, myoglobin, N-terminal pro-B-type natriuretic peptide, cardiac troponin I, big endothelin 1, and creatine kinase-MB, along with clinical and anthropometric factors.

View Article and Find Full Text PDF

Coronavirus Disease 2019 causes significant morbidity, and different variants of concern (VOCs) can impact organ systems differently. We conducted a single-center retrospective cohort analysis comparing biomarkers and clinical outcomes in hospitalized patients infected with the wild-type or Alpha (wt/Alpha) VOC against patients infected with the Omicron VOC. We included 428 patients infected with the wt/Alpha VOC and 117 patients infected with the Omicron VOC.

View Article and Find Full Text PDF

: Heart failure is associated with high morbidity and mortality and linked with several pre-existing health conditions and risk factors. Early detection and prompt management in heart failure improves patient outcomes. Liver involvement is associated with heart failure disease progression, and hence liver biomarkers and liver fibrosis may have a prognostic impact.

View Article and Find Full Text PDF

Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) drug used to treat patients with heart failure and has shown improvement in outcomes. Different studies reported the use of an ARNI in patients using left ventricular assist devices (LVADs). However, there are limited data on the use of ARNIs in this population.

View Article and Find Full Text PDF

Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors have been developed as a treatment for renal anemia. However, their therapeutic impact on patients with concomitant heart failure remains uncertain. We investigated the impact of HIF-PH inhibitors on improving renal anemia and associated clinical outcomes in patients with heart failure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!